✨
AI Summary
- Lilly's orforglipron shows promise in diabetic obesity.
- Ascletis confident in its oral GLP-1 challenger.
- Analysis of Dupixent's 'pipeline-in-a-product' success.
Guests on This Episode
OC
OneSource CEO
1 podcast appearance